Caspase activation is required for T cell proliferation by Kennedy,  N. J. et al.
 1891
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/99/12/1891/05 $5.00
Volume 190, Number 12, December 20, 1999 1891–1895
http://www.jem.org
 
Brief Definitive Report
 
Caspase Activation Is Required for T Cell Proliferation
 
By Norman J. Kennedy,
 
*
 
 Takao Kataoka,
 
‡
 
 Jürg Tschopp,
 
‡
 
and Ralph C. Budd
 
*
 
‡
 
From the 
 
*
 
Immunobiology Program, Department of Medicine, The University of Vermont College of 
Medicine, Burlington, Vermont 05405; and the 
 
‡
 
Institute of Biochemistry, University of Lausanne, 
BIL Biomedical Research Center, CH-1066 Epalinges, Switzerland
 
Summary
 
Triggering of Fas (CD95) by its ligand (FasL) rapidly induces cell death via recruitment of the
adaptor protein Fas-associated death domain (FADD), resulting in activation of a caspase cas-
cade. It was thus surprising that T lymphocytes deficient in FADD were reported recently to
be not only resistant to FasL-mediated apoptosis, but also defective in their proliferative capac-
ity. This finding suggested potentially dual roles of cell growth and death for Fas and possibly
other death receptors. We report here that CD3-induced proliferation and interleukin 2 pro-
duction by human T cells are blocked by inhibitors of caspase activity. This is paralleled by
rapid cleavage of caspase-8 after CD3 stimulation, but no detectable processing of caspase-3
during the same interval. The caspase contribution to T cell activation may occur via TCR-
mediated upregulation of FasL, as Fas-Fc blocked T cell proliferation, whereas soluble FasL
augmented CD3-induced proliferation. These findings extend the role of death receptors to
the promotion of T cell growth in a caspase-dependent manner.
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D
 
eath receptors typified by TNF receptor 1 (TNFR1)
and Fas mediate apoptosis in a wide array of cell types
through the ligand-induced association of adaptor proteins
that in turn recruit a series of aspartic acid–specific proteases
known as caspases (1). In the case of Fas, oligomerization of
FasL promotes the binding of Fas-associated death domain
protein (FADD) to the death domain of Fas (2). This allows
the association of caspase-8 and its activation through cleav-
age of a precursor to an active form. The resulting protease
cascade activates caspase-3, leading to eventual apoptosis (3).
Although activation-induced cell death (AICD) of T lym-
phocytes is well described as a Fas-dependent process for
previously activated cycling T cells, resting T cells are resis-
tant to Fas-mediated apoptosis (4, 5). This information, cou-
pled with the surprising observation that murine T cells either
deficient in FADD or expressing a dominant negative form of
FADD do not proliferate to TCR signals (6–9), further im-
plicates a required contribution by the death receptor path-
way in T cell growth. In these studies, we observe that CD3
stimulation of resting human T cells leads to processing of
caspase-8, but not of caspase-3, within 4 h of activation. In
addition, inhibitors of caspase activation block T cell prolif-
eration. Fas-Fc is also capable of blocking T cell growth,
suggesting that TCR-induced FasL upregulation may be at
least partly responsible for initiating caspase activation.
 
Materials and Methods
 
Cell Preparation, Proliferation, and IL-2 Assay. 
 
Purified human
T cells were prepared by Ficoll-Hypaque centrifugation followed
by rosetting with sheep erythrocytes. Positively rosetted lympho-
cytes were at least 98% CD3
 
1
 
 by flow cytometry. Purified T cells
were cultured in 96-well plates at 5 
 
3
 
 10
 
4
 
 cells per well and pre-
incubated for 30 min with the indicated concentrations of caspase
peptide blockers Ile-Glu-Thr-Asp fluoromethyl ketone (IETD-
fmk), benzyloxycarbonyl-Val-Ala-Asp (zVAD)-fmk, Asp-Glu-Val-
Asp (DEVD)-fmk, and Tyr-Val-Ala-Asp (YVAD)-fmk (Enzyme
Systems Products), or a similar dilution of the stock solvent DMSO.
Cells were then stimulated with the indicated concentrations of im-
mobilized anti-CD3 antibody TR66 at either an optimal concen-
tration of 3 
 
m
 
g/ml or suboptimally at 0.5 
 
m
 
g/ml. To some cultures
containing suboptimal anti-CD3 was added either soluble recombi-
nant fluoresceinated antigen (FLAG)-tagged FasL at the concentra-
tions shown (Alexis Corp.), with or without cross-linking by 1 
 
m
 
g/
ml of anti-FLAG antibody (M2; Sigma Chemical Co.); with soluble
IgM anti-CD28 antibody 28/34 at 5 
 
m
 
g/ml; or with immobilized
Fas-Fc (Alexis Corp.); or human IgG at the concentrations shown.
Proliferation was measured by tritiated thymidine ([
 
3
 
H]TdR) incor-
poration during the final 18 h of a 4-d culture. Supernatants for IL-2
production were taken from PBLs (10
 
6
 
/ml) that were stimulated for
24 h with immobilized anti-CD3 (3 
 
m
 
g/ml), with or without each
caspase blocker (50 
 
m
 
M), or with cross-linked FasL (50 ng/ml). IL-2
levels were assayed using the CTLL bioassay.
 
Western Blots. 
 
Cells were washed once with PBS, and lysed in
lysis buffer (50 mM Tris-HCl, pH 7.5), 1% Triton X-100, 2 mM
dithiothreitol, 2 mM sodium vanadate, and protease inhibitor cock-
tail (Complete™; Boehringer Mannheim), followed by centrifuga-
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tion. Postnuclear lysates from 2 
 
3
 
 10
 
6
 
 cells per lane were separated
by SDS-PAGE, and analyzed by Western blotting using antibodies
to caspase-3 (Transduction Laboratories) or caspase-8 (PharMingen).
 
Cell Cycle Analysis. 
 
Cells were stimulated by immobilized
anti-CD3 (0.5 
 
m
 
g/ml), anti-CD3/FasL (50 ng/ml plus anti-
FLAG, 1 
 
m
 
g/ml), anti-CD3/anti-CD28 (28/34, IgM soluble at
10 
 
m
 
g/ml), or medium control. Samples were taken on each day
for 5 d, washed in PBS, and then stained in 250 
 
m
 
l using 50 
 
m
 
g/ml
propidium iodide (PI) in 0.1% Triton X-100, 4 mM sodium citrate,
and 360 U/ml RNase, pH 7.2. Cells were incubated for 30 min
at 37
 
8
 
C, and then 250 
 
m
 
l of salt solution was added (50 
 
m
 
g/ml PI,
0.1% Triton X-100, 0.4 M NaCl, pH 7.2). Samples were stored
in the dark at 4
 
8
 
C for at least 1 h, and then analyzed within 24 h by
flow cytometry.
 
Results and Discussion
 
T Cell Proliferation Is Caspase Dependent.
 
Stimulation of
purified resting human T lymphocytes by anti-CD3 anti-
body was extensively blocked by the caspase inhibitors
IETD-fmk and zVAD-fmk over a dose range of 12.5–50 
 
m
 
M
(Fig. 1 A). By contrast, two other caspase blockers, YVAD-
fmk and DEVD-fmk, showed no inhibition of T cell growth
at similar concentrations. Although differences in the speci-
ficity of these caspase blockers has been suggested, they are
actually irreversible blockers, with the ability to titrate all
accessible caspases. Thus, the different degrees of inhibition
by the various blockers should not be viewed as implicating
a particular caspase. An alternative explanation for the dif-
ferences would be varying degrees of permeability by the
caspase blockers in primary T cells.
We also considered the possibility of nonspecific toxicity
selectively by IETD-fmk and zVAD-fmk. However, the
addition of exogenous IL-2 to cultures containing IETD-
fmk or zVAD-fmk could largely overcome the block in
proliferation (data not shown). Furthermore, to block pro-
liferation, the addition of IETD-fmk had to occur within
the first 24 h of CD3 stimulation, after which it conferred
no inhibition even at relatively high concentrations of 50 
 
m
 
M
(Fig. 1 B). This observation also underscores the view that
a caspase is involved in early T cell activation events, and
that evidence of its processing should therefore be exam-
ined early, before secondary activation-induced cell death
Figure 1. CD3-induced T cell prolifera-
tion is blocked by inhibitors of caspases and
Fas-Fc, and augmented by FasL. (A) Rest-
ing purified human T cells were stimulated
with immobilized anti-CD3 (3 mg/ml) in
the presence of the indicated concentrations
of the caspase inhibitors IETD-fmk, zVAD-
fmk, DEVD-fmk, and YVAD-fmk, or control
DMSO at the same dilution. Proliferation
was monitored by [3H]TdR incorporation
after 3 d. (B) T cells were stimulated with
immobilized anti-CD3 (3 mg/ml) in the ab-
sence or presence of IETD (50 mM), added
on the days indicated. Proliferation was de-
termined after 3 d. (C) T cells were acti-
vated with immobilized anti-CD3 (0.5 mg/
ml) in the presence of either immobilized
Fas-Fc or human IgG at the indicated con-
centrations. (D) Resting T cells were stimu-
lated with suboptimal immobilized anti-CD3
(0.5 mg/ml) in the presence of the indicated
concentrations of soluble FLAG-tagged
FasL, with or without cross-linking by anti-
FLAG. A comparison for costimulation is
shown using the same concentrations of
bound anti-CD3 and soluble IgM anti-
CD28 (e). (E) Proliferation of T cells by
anti-CD3 (0.5 mg/ml) in the absence or
presence of cross-linked FasL (50 ng/ml),
added on the days indicated. (F) T cells
were cultured with the indicated caspase in-
hibitors, and stimulated with anti-CD3 (0.5
mg/ml) and cross-linked FasL (50 ng/ml).
Similar results were observed in three ex-
periments.
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(AICD) complicates the picture, as cycling T cells become
sensitive to FasL-induced apoptosis.
A possible sequence by which TCR stimulation could
activate the caspase cascade would be via the known TCR-
induced upregulation of FasL (10) that would in turn en-
gage surface Fas. Consistent with this view, immobilized
Fas-Fc, but not control human IgG, largely blocked subop-
timal (0.5 
 
m
 
g/ml) anti-CD3 activation of T cell growth in
a dose-dependent manner (Fig. 1 C). This finding does not
exclude the additional possibility that Fas-Fc might also
confer a negative signal directly retrograde through FasL
(11). However, in agreement with the former model, the
addition of soluble FasL to suboptimal doses of anti-CD3
promoted a dose-dependent increase of T cell growth by as
much as threefold (Fig. 1 D). At higher concentrations of
anti-CD3 (3.0 
 
m
 
g/ml), there was less block of proliferation
by Fas-Fc, and less augmentation of proliferation by FasL
(data not shown). This is in agreement with similar findings
using anti-Fas antibodies (12; our unpublished observations).
The magnitude of this costimulation approached that seen
with the same concentration of anti-CD3 and an optimal
dose of anti-CD28. FasL costimulation was observed only
when FasL was oligomerized through cross-linking of its
FLAG tag using anti-FLAG, which mimics active mem-
brane-bound FasL (13). As with the caspase blockers, co-
stimulation with FasL needed to be delivered within the
first 24 h of CD3 activation, otherwise no effect was ob-
served (Fig. 1 E). Similar to the findings with CD3 stimula-
tion, the costimulation of T cell growth conferred by FasL was
also blocked by the same two caspase inhibitors (Fig. 1 F).
 
CD3 Activation and CD3/FasL Costimulation Cleave
Caspase-8.
 
Evidence for activation of caspase-8 and cas-
pase-3 was investigated by Western blot within 2–4 h of
T cell activation by anti-CD3, with or without FasL (Fig.
2 A, top). Purified resting T cells were treated with immo-
bilized suboptimal anti-CD3 (0.5 
 
m
 
g/ml) antibody in the
absence or presence of cross-linked FasL or with cross-
linked FasL alone, and caspase processing was analyzed dur-
ing the first 4 h. Given the need to block caspase activity
within the first 24 h, we elected to examine early time in-
tervals after activation. It was also reasoned that evidence of
caspase processing after this time might reflect FasL-induced
apoptosis of actively dividing T cells.
Caspase-8 processing in primary T cells is detectable by
cleavage of its full-length 55-kD form between the pro-
caspase and caspase domains to release a cleaved 28-kD frag-
ment. As shown in Fig. 2 A, no evidence of caspase-8 cleav-
age was detectable in unstimulated T cells for up to 4 h, or
even after overnight culture (data not shown). However,
cleavage of caspase-8 became apparent by 4 h after subopti-
mal anti-CD3 stimulation (0.5 
 
m
 
g/ml) alone, or within 2 h
using anti-CD3 plus FasL (Fig. 2 A). This was particularly
visible by longer exposure of the blot (Fig. 2 A, bottom).
Similar to the proliferation findings, the amount of the
cleaved p28 fragment was more intense at high doses of
anti-CD3 (3.0 
 
m
 
g/ml), but less augmentation by FasL was
observed (data not shown). Thus, FasL costimulation was
best observed for both proliferation and caspase-8 process-
ing at suboptimal doses of anti-CD3. The cleavage of
caspase-8 was not secondary to apoptosis, as 
 
,
 
1% cell death
was detectable by PI staining in either the unstimulated
controls or stimulated cultures up to 24 h later (data not
shown). Furthermore, IETD-fmk, but not DEVD-fmk or
YVAD-fmk, at the same dose (50 
 
m
 
M) that inhibited T cell
growth also blocked cleavage of caspase-8 during anti-
CD3/FasL costimulation over 6 h (Fig. 2 A).
Although caspase-3 cleavage was readily detectable in
FasL-treated Jurkat T cells undergoing apoptosis (Fig. 2 B),
Figure 2. CD3/Fas costimulation results in cleavage
of caspase-8, but not of caspase-3. (A) Purified human
T cells (98%) were cultured with either no stimulation
(Control), immobilized anti-CD3 alone (0.5 mg/ml),
anti-CD3 plus soluble FasL (50 ng/ml) cross-linked by
its FLAG tag, or cross-linked FasL alone. Cell lysates
were made after the indicated times of culture, and
were analyzed sequentially by Western Blot for expres-
sion of cleaved forms of caspase-8 and caspase-3. The
full-length forms (Pro) of the proteins are indicated by
the black arrowheads, whereas the cleaved forms are
indicated with open arrowheads. The larger top panels
for each caspase show exposure times of 5 min,
whereas the smaller bottom panels represent 30-min
(caspase-8) or 60-min (caspase-3) exposures. An addi-
tional three samples of T cells were stimulated with anti-
CD3/FasL for 6 h in the presence of the caspase-8
blocker IETD-fmk, caspase-3 blocker DEVD-fmk, or
caspase-1 blocker YVAD-fmk, each at 50 mM. The ra-
tio of procaspase to cleaved caspase-8, assessed by den-
sitometry, is indicated in parentheses. (B) Positive con-
trol for cleavage of caspase-3 in Jurkat T cells treated
with cross-linked FasL (50 ng/ml) for the times indi-
cated. The levels of cell death by PI staining were con-
sistently ,1% in all cultures except the sample with
IETD, which in one experiment was 4.2%. These find-
ings were consistent in two additional experiments.
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no indication of caspase-3 cleavage products could be
found in primary T cells costimulated with anti-CD3/FasL
over 4 h, even with longer exposure of the blot (Fig. 2 A,
bottom), or with costimulation for as long as 22 h (data not
shown). Consequently, cleavage of poly(ADP-ribose) poly-
merase (PARP), a substrate for caspase-3, was also not ob-
served (data not shown). This indicated that processed
caspase-8 did not lead to detectable processing of caspase-3
under these conditions of CD3/Fas costimulation.
 
FasL Costimulation Increases IL-2 Production and Cell Cycling.
 
The augmented proliferation conferred by anti-CD3/FasL
was paralleled by increased production of IL-2, which was
also blocked by IETD-fmk and zVAD-fmk (Fig. 3 A). As
IL-2 promotes entry of T cells into the S phase of the cell
cycle, the effect of FasL costimulation on cell cycling was
examined. As shown for day 4 in Fig. 3 B, and summarized
for all days in Table I, FasL costimulation with CD3 in-
creased the percentage of cells in S
 
1
 
G2
 
1
 
M over CD3
alone, to levels at least as high as observed with CD3 plus
CD28 activation. Furthermore, the increased proliferation
with FasL could be at least partly blocked by addition of
anti-CD25 (Fig. 3 C), suggesting that FasL costimulation
may occur partly through upregulation of cytokines neces-
sary for T cell proliferation.
Combined with the reported T cell activation defect in
FADD-deficient mice and FADD-dominant negative mice
(6–9), the current findings suggest a model whereby T cell ac-
tivation via TCR upregulates surface FasL, which engages Fas
and leads to recruitment of FADD and caspase activation.
However, in resting T cells, this does not result in apoptosis,
but rather augments IL-2 gene activation and cell proliferation.
The notion that FasL can augment proliferation of resting
T cells may be more broadly applicable to other death recep-
tors such as TNF-related apoptosis-inducing ligand receptor
(TRAIL-R) and TNFR-related apoptosis-mediated receptor/
death receptor 3 (TRAMP/DR3) (1), as well as to other cell
types. These other death receptors may be particularly impor-
tant in initiating proliferation of primary T cells lacking Fas. In
addition to T cells, fibroblasts have also been observed to man-
ifest increased proliferation with anti-Fas antibodies (12, 14), as
well as with FasL (our unpublished observations).
The exact caspase(s) required for proliferation by primary
T cells and its substrate cannot be concluded at present,
given the broad specificity of the caspase blockers. However,
one might speculate that a proximal caspase in the Fas signal
cascade is required for activation of primary T cells, given
our findings of cleavage of caspase-8, but not of caspase-3,
under conditions of FasL costimulation. A likely substrate
for caspase-8 by which a death signal could be diverted to a
proliferative response would be cellular FADD-like IL-1
 
b
 
–
converting enzyme (FLICE) inhibitory protein (c-FLIP), the
natural inhibitor of Fas-induced cell death. c-FLIP is homol-
ogous to caspase-8, but bears a nonfunctional caspase domain.
c-FLIP contains two potential caspase cleavage sites, and as
such functions as a substrate trap for caspase-8, while also
competing for binding to FADD (15). In further studies we
have observed that c-FLIP is cleaved during T cell activa-
Figure 3. Caspase blocking inhibits IL-2 production, which is aug-
mented by FasL along with cell cycling. (A) T cells were cultured at 106/ml
with immobilized anti-CD3 and cross-linked FasL in the absence or pres-
ence of the indicated caspase inhibitors (50 mM). Supernatants were re-
moved after 24 h and assayed for IL-2 using the CTLL bioassay. (B) Cell
cycle analysis using PI was performed daily for 5 d on T cells after stimu-
lation with the indicated agents. Shown are the results on day 4 from one
experiment. All time points of two separate experiments are summarized
in Table I. (C) T cells were activated with anti-CD3 in the absence or
presence of FasL. To cultures stimulated by anti-CD3 plus FasL was
added either no additional antibody, anti-CD25 (25 mg/ml, 12.5 mg/ml),
or control IgG (25 mg/ml). Proliferation was measured after 3 d.
 
Table I.
 
Increased Cell Cycling with CD3/FasL Costimulation
 
Stimulus
Percentage of cells in S
 
1
 
G2
 
1
 
M
Day 1 Day 2 Day 3 Day 4 Day 5
Experiment 1
Medium 2.6 2.6 3.6 3.4 3.9
 
a
 
-CD3 6.8 5.0 8.8 5.8 7.5
 
a
 
-CD3/FasL 11.9 9.2 14.7 9.5 10.1
FasL 3.4 4.5 4.2 5.2 4.6
 
a
 
-CD3/
 
a
 
-CD28 6.2 10.5 10.3 9.7 7.9
Experiment 2
Medium 5.1 4.6 2.1
 
a
 
-CD3 6.5 7.5 4.2
 
a
 
-CD3/FasL 9.6 15.2 12.2
FasL 3.6 3.5 1.7
T cells were activated by the indicated stimulus, and samples were
taken on the days shown, permeabilized, and stained with PI. Cell cycle
analysis was performed by flow cytometry, and gates were set for the
S
 
1
 
G2
 
1
 
M phases of the cell cycle.
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tion, and its overexpression in Jurkat T cells or in transgenic
mouse T cells increases the activities of the mitogen-acti-
vated protein (MAP) kinase, extracellular signal–regulated
kinase (ERK), and nuclear factor (NF)-
 
k
 
B after CD3 stim-
ulation, leading to augmented IL-2 production. In addition,
Fas costimulation of normal T cells with CD3 also aug-
ments the activator protein 1 (AP-1) and NF-
 
k
 
B pathways
(our manuscript in preparation). It is apparent from these
findings that inhibitors of caspases could prove valuable in
therapeutic maneuvers to diminish T cell activation.
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